Roche provides update on phase III study of Gazyva/Gazyvaro
Monday, July 18, 2016 - 10:11
in Health & Medicine
GOYA study did not meet its primary endpoint of improvement in progression-free survival with Gazyva/Gazyvaro plus CHOP chemotherapy versus MabThera/Rituxan plus CHOP chemotherapy Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III GOYA study evaluating Gazyva®/Gazyvaro® (obinutuzumab) plus CHOP chemotherapy (G-CHOP) in people with previously untreated diffuse large B-cell lymphoma (DLBCL) did […]